



Atty. Dkt. No. 034536-1148

IFW
bexug

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jingrong Jean CUI et al.

Title: AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE
INHIBITORS

Appl. No.: 10/786,610

Filing Date: 02/26/2004

Examiner: Unassigned

Art Unit: 1614

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98. Copies of documents B2 – B10 are being submitted herewith on a CD-R. Paper copies of documents B1 and B11 – B18 are submitted herewith.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE


The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 29 September 2004


By 

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known		
				Application Number		10/786,610
				Filing Date		02/26/2004
				First Named Inventor		Jingrong Jean CUI
				Group Art Unit		1614
				Examiner Name		Unassigned
Sheet 1 of 2				Attorney Docket Number		034536-1148



FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	JP	07-109260	A	FUJI PHOTO FILM CO LTD	04-25-1995		
	B2	EP	0 204 285	B1	FUJISAWA PHARMACEUTICAL CO., LTD.	01-15-1992		
	B3	EP	1 044 967	B1	PFIZER INC. & PFIZER LIMITED	08-11-2004		
	B4	WO	93/15055	A1	SMITHKLINE BEECHAM INTERCREDIT B.V.	08-05-1993		
	B5	WO	99/55706	A1	ASTRA AKTIEBOLAG	11-04-1999		
	B6	WO	01/00213	A1	MERCK & CO., INC.	01-04-2001		
	B7	WO	01/60806	A2	NEUROGEN CORPORATION	08-23-2001		
	B8	WO	02/056882	A1	SMITHKLINE BEECHAM P.L.C.	07-25-2002		
	B9	WO	03/000666	A1	PFIZER PRODUCTS INC.	01-03-2003		
	B10	WO	03/045924	A1	PHARMACIA & UPJOHN COMPANY	06-05-2003		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B11	BRADBURY et al., "New Non-Peptide Endothelin-A Receptor Antagonists: Synthesis, Biological Properties, and Structure – Activity Relationships of 5-(Dimethylamino)-N-pyridyl-, -N-pyrimidinyl-, -N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides," <i>J. Med. Chem.</i> , 1997, pp. 996-1004, Vol. 40, No. 6	
	B12	BRISTOL et al., "An Improved Synthesis of 2-Amino-3-alkyloxypyridines by a Phase-Transfer Catalyzed Ether Synthesis," <i>Synthesis</i> , December 1981, pp. 971-973, Vol. 12	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/786,610		
		Filing Date	02/26/2004		
		First Named Inventor	Jingrong Jean CUI		
		Group Art Unit	1614		
		Examiner Name	Unassigned		
Sheet	2	of	2	Attorney Docket Number	034536-1148

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B13	DENNIN, et al., "Synthesis of Derivatives of Pyrazino[1,2-a]pyrimidin-4-ones," <u>Journal of Heterocyclic Chemistry</u> , September-October 1990, pp. 1639-1643, Vol. 27	
	B14	FOKS et al., "Studies on Pyrazine Derivatives. XXX. Sythesis of Pyrazinylamino-1,3-Diazacycloalkanes of Potential Circulatory Activity," <u>Acta Poloniae Pharmaceutica</u> , January/February 1997, pp. 55-62, Vol. 54, No. 1	
	B15	KAMINSKI et al., "Antiulcer Agents. 2. Gastric Antisecretory, Cytoprotective, and Metabolic Properties of Substituted Imidazo[1,2-a]pyridines and Analogues," <u>J. Med. Chem.</u> , 1987, pp. 2031-2046, Vol. 30	
	B16	SHIMOMURA et al., "Semi-synthetic aequorins with improved sensitivity to Ca ²⁺ ions," <u>Biochem. J.</u> , 1989, pp. 913-920, Vol. 261	
	B17	SOLLOGOUB et al., "First synthesis of 1-deazacytidine, the C-nucleoside analogue of cytidine," <u>Tetrahedron Letters</u> , 2001, pp. 3121-3123, Vol. 43	
	B18	WISTEROWICZ et al., <u>Acta Poloniae Pharmaceutica</u> , 1997, pp. 55-62, Vol. 54, No. 1	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.